Mandragora

# Research Output: Mandragora

## Botanical Identity

**Accepted taxonomy:** *Mandragora officinarum* L. — first published in Linnaeus, *Species Plantarum*: 181 (1753). Family: **Solanaceae**; Order: Solanales; Class: Equisetopsida; Kingdom: Plantae [Ref 10].

**Native range:** Northern Italy to the northwestern Balkan Peninsula; also Lebanon-Syria. A perennial of the temperate biome [Ref 10].

**Accepted synonyms (POWO):** *Atropa mandragora* L.; *Atropa humilis* Salisb.; *Mandragora acaulis* Gaertn.; *Mandragora neglecta* G.Don; *Mandragora praecox* Sweet; *Mandragora vernalis* Bertol.; *Mandragora officinalis* Mill. ex DC. [Ref 10].

**Genus revision (1998):** Ungricht, Knapp, and Press produced the authoritative taxonomic revision of the genus *Mandragora* (Solanaceae) [Ref 6]. The genus currently comprises three recognized species of pharmacological significance:
- *M. officinarum* L. — spring mandrake; native to N. Italy, NW Balkans, and Lebanon-Syria
- *M. autumnalis* Bertol. — autumn mandrake; native to the broader Mediterranean basin, including North Africa (Morocco, Algeria) and the Levant
- *M. turcomanica* Mizgir — Central Asian mandrake; Turkmenistan/Afghanistan region

**Cultivation status:** Primarily wild-harvested across its native range. No established commercial cultivation for pharmaceutical or supplement markets has been documented in the peer-reviewed literature. Grown occasionally as an ornamental in temperate gardens in Europe and the UK.

**Morphology and misidentification risk:** *Mandragora* is acaulescent (stemless), forming a basal rosette of large, wrinkled leaves. The root is large, often branched, and frequently anthropomorphic in shape — a cultural observation that drove centuries of mythology. The orange-yellow berries (approximately the size of a cherry tomato) ripen in spring and have been mistaken for edible plants, particularly borage (*Borago officinalis*) and other herbs. This is documented in clinical case reports: two adults in Crete were hospitalized after eating Mandragora berries they had mistaken for borage (Tsiligianni et al. 2009 [Ref 29]). In North America, the name "mandrake" is also applied to *Podophyllum peltatum* (American mandrake/mayapple), a completely unrelated plant with different toxicology — the distinction has caused confusion in clinical settings (Frasca et al. 1997 [Ref 5]).

**Brief note on seed data:** The brief contained no botanical seed data (family, genus, native range). The above has been fully sourced from POWO and peer-reviewed taxonomy.

---

## Alkaloid / Cannabinoid Profile

### Primary alkaloid class: Tropane alkaloids

Mandragora species belong to the tropane alkaloid-producing lineage of the Solanaceae family (Shim et al. 2022 [Ref 1]; Pomilio et al. 2008 [Ref 12]). Over 80 distinct substances have been identified from all parts of the genus (Hanus et al. 2005 [Ref 22]).

**Critical inter-species alkaloid divergence** (Schlesinger et al. 2019 [Ref 20]):
- *M. officinarum* and *M. turcomanica* contain **high levels of hyoscyamine** but lack anisodamine and scopolamine entirely.
- *M. autumnalis* contains **both hyoscyamine and scopolamine**, with up to 10-fold lower hyoscyamine than *M. officinarum*.
- The molecular basis: a single G→T mutation at nucleotide 663 of the *MoH6H* gene in *M. officinarum* renders hyoscyamine 6β-hydroxylase (H6H) — the enzyme that converts hyoscyamine to anisodamine and then to scopolamine — functionally inactive. The *MaH6H* gene in *M. autumnalis* encodes an active H6H enzyme.

**HPLC-DAD quantification (Piatti et al. 2025 [Ref 21]):** In a comparative study of four Solanaceae using HPLC-DAD:
- *A. belladonna*: hyoscyamine 1,466–5,117 mg/kg DW; scopolamine 140–1,743 mg/kg DW
- *D. stramonium*: scopolamine 430–8,980 mg/kg DW (no hyoscyamine)
- *H. niger*: no hyoscyamine or scopolamine detected
- *M. officinarum*: **no hyoscyamine or scopolamine detected** in the tested accessions

⚠️ **Discrepancy flag:** The Piatti 2025 HPLC study found no detectable alkaloids in their *M. officinarum* specimens, while Schlesinger 2019 confirmed biochemically that *M. officinarum* contains high hyoscyamine. This likely reflects accession, plant-part, or sample-preparation differences rather than a fundamental contradiction. Older literature and many review articles (including Monadi 2021 [Ref 36]) describe both atropine and scopolamine as present in the genus, often without species-level differentiation. Generation agent should note this uncertainty when characterizing the alkaloid profile.

**Quantified data for *M. autumnalis*:** Roots at flowering stage contain approximately 0.2% atropine-equivalent alkaloids by capillary gas chromatography (cited in multiple reviews; no primary GC source retrieved directly).

**Identified alkaloids across the genus** (Hanus 2005 [Ref 22]; Monadi 2021 [Ref 36]; Suleiman 2010 [Ref 37]):
- Hyoscyamine (dominant in *M. officinarum*, *M. turcomanica*; [[substance:hyoscyamine]] on first mention)
- Scopolamine / hyoscine (dominant in *M. autumnalis*; [[substance:scopolamine]] on first mention)
- Atropine (racemate of hyoscyamine; [[substance:atropine]])
- Cuscohygrine (PubChem CID 1201543; C₁₃H₂₄N₂O)
- Apoatropine
- 3-alpha-tigloyloxytropane
- 3-alpha,6-beta-ditigloyloxytropane
- Belladonnine

**Non-alkaloid constituents** (Suleiman 2010 [Ref 37]; Monadi 2021 [Ref 36]; Al-Maharik 2022 [Ref 24]):
- **Withanolides:** Mandragorolide A and B (novel, first isolated from *M. officinarum*, Jordanian origin); larnaxolide A; withanolide B; datura lactone 2; withanicandrin; salpichrolide C. First report of withanolides from the genus *Mandragora* (Suleiman 2010).
- **Coumarins:** Umbelliferone; scopoletin (five coumarins identified from *M. autumnalis* roots, leaves, and unripe fruits)
- **Flavonoids (M. autumnalis fruit):** Kaempferol, luteolin, myricetin, (+)-taxifolin (Al-Maharik et al. 2022 [Ref 24])
- **Sterols:** β-sitosterol

**PubChem verified CIDs:**
- Scopolamine: CID 3000322; C₁₇H₂₁NO₄; MW 303.35; InChIKey STECJAGHUSJQJN-USLFZFAMSA-N [Ref, PubChem database lookup]
- Hyoscyamine: CID 154417; C₁₇H₂₃NO₃; MW 289.4; InChIKey RKUNBYITZUJHSG-VFSICIBPSA-N [Ref, PubChem database lookup]
- Atropine: CID 174174; C₁₇H₂₃NO₃; MW 289.4; InChIKey RKUNBYITZUJHSG-PJPHBNEVSA-N [Ref, PubChem database lookup]

**Mandragorine:** Commonly cited in older popular literature as the defining alkaloid of mandrake — not found in PubChem under this name; appears to be a historical synonym or misidentification. Flag for human review.

---

## History & Ethnobotany

**First scientific description:** Linnaeus, *Species Plantarum* (1753), who formalized the binomial *Mandragora officinarum* L.

**Ancient Near East and Biblical record:** Mandrake (*Mandragora officinarum*) is one of only five plants mentioned directly as medicinal in the Hebrew Bible, appearing in Genesis 30:14-16 ("dudaim") in connection with fertility and aphrodisiac use (Dafni & Böck 2019 [Ref 8]). The plant was also known in ancient Egypt and Mesopotamia, where it featured in medical and ritual contexts. Dafni & Böck propose that all confirmed biblical medicinal plants have been in continuous medicinal use in the Middle East across generations.

**Greek and Roman medicine:** Pedanius Dioscorides (De Materia Medica, 1st century AD) is the first to explicitly describe administration of mandrake-induced anesthesia to facilitate surgical intervention — recording a dose of approximately 1 cyathus (~45 ml) of a root decoction boiled in wine (reduced to one-third volume) before surgical procedures. Pliny the Elder documented similar applications. Traditional preparation forms included: fresh root juice, root boiled in wine (reduction), root bark infusion, and sun-dried fruit. These are traditional-use accounts — flag for human review.

**Medieval European use:** The "spongia somnifera" (soporific sponge) — used in medieval surgery — incorporated mandrake among other narcotic plants (henbane, opium) as an inhalation or topical preparation for anesthesia (Cavalloro et al. 2023 [Ref 25]). The 13th-century physician Teodorico Borgognoni is identified as a forerunner of modern anesthesia whose formulary included narcotic plant preparations.

**Witches' flying ointment:** Among the most documented traditional applications of mandrake in European historical sources is its inclusion in "unguentum sabbati" (witches' ointment) recipes — typically combined with belladonna, henbane (*Hyoscyamus niger*), and sometimes monkshood (*Aconitum*), rendered in animal fat and applied transdermally. The anticholinergic alkaloids (particularly scopolamine from *M. autumnalis* in Mediterranean regions) are pharmacologically capable of transdermal absorption, producing intense delirium, hallucinations, and sensory distortions interpreted as "flying." This pharmacological explanation for the witch-trial confession tradition has been proposed and debated by historians. The Fatur & Kreft 2021 study found that among contemporary hallucinogen users in Slovenia, knowledge of anticholinergic Solanaceae has been largely lost — attributed to their severe toxicity and characteristically unpleasant effects compared to other hallucinogens [Ref 30].

**Vernacular names:** Dafni et al. (2021) analyzed 292 vernacular names for *Mandragora* spp. across 41 languages, finding the most common name-categories relate to: anthropomorphism (33 names), similarity to other plants (28), supernatural agents (28), narcotic effects (21), and aphrodisiac properties (17) [Ref 9]. The spatiotemporal analysis supports the Near East as the origin of the plant's pulling ceremony mythology.

**Ethnobotany across cultures:** Monadi et al. (2021) document traditional uses across the Mediterranean basin, Europe, North Africa, and Himalayan regions including: insomnia, dysuria, hemorrhoids, rheumatic pain, toothache, melancholia, and depression [Ref 36]. Traditional Arab herbal medicine in the Eastern Mediterranean has incorporated Mandragora species [Ref 40]. ⚠️ All traditional-use claims are traditional-use accounts without clinical confirmation — flag for human review.

**Western pharmaceutical interest:** Hyoscyamine and scopolamine (from *M. autumnalis* and related species) have been used clinically since the 19th century for anesthesia premedication, motion sickness (scopolamine patches), ophthalmology (mydriasis), and gastrointestinal disorders. The FDA has approved atropine and scopolamine formulations; both are on the WHO List of Essential Medicines (Shim et al. 2022 [Ref 1]). Research interest in *Mandragora* specifically declined as synthetic anticholinergics became available.

---

## Neuroscience & Mechanism

**Primary receptor targets:** The dominant alkaloids in *Mandragora* — hyoscyamine, atropine, and (in *M. autumnalis*) scopolamine — are competitive antagonists of muscarinic acetylcholine receptors (M₁–M₅). This mechanism is thoroughly characterized for the pure compounds, which serve as the pharmacological basis for the plant's effects (Lakstygal et al. 2019 [Ref 13]; Shim et al. 2022 [Ref 1]).

**CNS vs. peripheral activity:** Scopolamine has greater CNS penetrance than atropine/hyoscyamine, producing more pronounced sedation, amnesia, and hallucinations at lower doses relative to peripheral effects. Hyoscyamine (and its racemate atropine) produce prominent peripheral anticholinergic effects: mydriasis, cycloplegia, dry mouth, anhidrosis, tachycardia, urinary retention, decreased bowel motility, bronchodilation.

**Deliriant mechanism:** At higher doses, central muscarinic blockade produces a characteristic deliriant syndrome — not psychedelic (no serotonergic or glutamatergic involvement) — characterized by disoriented, confused, agitated delirium; vivid but fragmented hallucinations (frequently visual, tactile); complete or partial amnesia for the episode; and inability to distinguish the hallucinated state from reality. This is qualitatively distinct from classic psychedelic hallucinogens (Lakstygal et al. 2019 [Ref 13]).

**Pharmacokinetics by route:**
- *Oral route (scopolamine):* Tmax ~0.5 hours; oral bioavailability 3–27% (high first-pass effect; CYP3A demethylation); only 2.6% excreted unchanged in urine (Renner et al. 2005 [Ref 14])
- *Transdermal (scopolamine patch):* Cmax ~100 pg/mL (range 11–240 pg/mL) at approximately 8 hours; steady-state maintained 56–245 pg/mL over 72 hours (Renner 2005 [Ref 14]; Pensado et al. 2021 [Ref 32])
- *Hyoscyamine:* More potent than atropine at muscarinic receptors (same molecular backbone, different stereochemistry); pharmacokinetics closely parallel atropine
- No published pharmacokinetic data exists for whole-plant *Mandragora* preparations in humans

**CYP enzyme involvement:** Scopolamine undergoes oxidative N-demethylation via CYP3A4 in the intestinal wall and liver. Grapefruit juice (CYP3A intestinal inhibitor) increases scopolamine AUC to approximately 142% of control and significantly prolongs Tmax (Renner 2005 [Ref 14]).

**Blood-brain barrier:** Both scopolamine and hyoscyamine cross the BBB readily; scopolamine at clinical doses produces demonstrable CNS effects. The placenta is also permeable to these alkaloids (Renner 2005 [Ref 14]).

---

## Effects & Dose by Preparation

⚠️ **MAJOR FLAG:** No published controlled human dose-response studies exist for *Mandragora* plant preparations. All dose thresholds below are derived from historical accounts, clinical toxicology case reports, or extrapolation from pharmaceutical literature on isolated alkaloids. All dose values must be flagged for human review before inclusion in any database field.

### Oral preparation (root decoction / wine reduction)
- *Historical dose for anesthesia:* Approximately 1 cyathus (~45 ml) of mandrake root boiled in wine to one-third volume, taken orally (Dioscorides, 1st century AD; cited in multiple historical reviews). This is traditional-use data only — flag for human review.
- *Modern context:* No controlled human studies. Case reports describe severe anticholinergic toxidrome from accidental ingestion of unspecified quantities of berries or root material.
- *Onset:* Likely 30–60 minutes (consistent with oral anticholinergic pharmacokinetics, based on pharmaceutical scopolamine data)
- *Duration:* 4–8+ hours based on anticholinergic kinetics; severe poisoning cases showed persistent supraventricular tachycardia for up to 5 days (Tsiligianni 2009 [Ref 29])

### Topical/transdermal preparation (historical flying ointment)
- *Preparation:* Plant material in animal fat (lard or tallow); applied to skin, particularly axillary and perineal regions or mucosal surfaces where absorption is most efficient
- *Onset:* Transdermal scopolamine Tmax ~8 hours (commercial patch). Historical ointments were not standardized; absorption was variable.
- *Evidence base:* Transdermal absorption of tropane alkaloids through skin is pharmacologically validated (Pensado 2021 [Ref 32]). The specific claim that flying ointments produced hallucinatory experiences is traditional-use / historical speculation — no controlled pharmacological study of historical recipes exists. Flag for human review.

### Dose-effect relationship (general framework from anticholinergic pharmacology)
Based on pharmaceutical literature for isolated alkaloids, NOT Mandragora plant preparations:
- *Low/sedating doses:* Drowsiness, mild dry mouth, slight tachycardia, blurred vision
- *Moderate doses:* Marked mydriasis, pronounced dry mouth, urinary retention, tachycardia, sedation; hallucinations may begin
- *High/toxic doses:* Delirium with agitation, vivid fragmented hallucinations, complete amnesia, hyperthermia, severe tachycardia, death possible from respiratory depression and cardiovascular failure

**Fatal dose:** No LD50 established for whole-plant preparations in humans. Traditional accounts cite doses as low as 3–6 g of dried root material as potentially fatal; alkaloid content variability across plant parts, species, and developmental stage makes any fixed lethal dose unreliable.

---

## Safety & Toxicity

### Anticholinergic toxidrome
Classic clinical presentation of anticholinergic poisoning (applicable to *Mandragora*):
- "Hot as a hare" — hyperthermia, anhidrosis
- "Dry as a bone" — dry mucous membranes, absent salivation, urinary retention
- "Red as a beet" — flushed skin from vasodilation
- "Blind as a bat" — mydriasis, cycloplegia, blurred near vision
- "Mad as a hatter" — delirium, agitation, hallucinations, amnesia

### Clinical case reports

**Tsiligianni et al. 2009 (Crete, Greece) [Ref 29]:** Two adults from the same family presented after eating Mandragora berries mistaken for borage. Symptoms: nausea, dizziness, blurred vision, dry mouth, headache, instability in walking, vomiting; flushed skin, reactive mydriasis, pulse rates 190 and 170 bpm; supraventricular tachycardia on ECG. Treatment: physostigmine 1 mg IV per day, following gastric lavage. Neurologic symptoms resolved within 2 days; supraventricular tachycardia persisted for 5 days; liver enzymes normalized within 10 days. Full recovery. No confirmatory toxicology performed.

**Nikolaou et al. 2012 [Ref 4]:** Accidental poisoning after ingestion of *Mandragora officinarum* berries believed to be aphrodisiac. Diagnostic analytical toxicology confirmed plant identity.

**Frasca et al. 1997 [Ref 5]:** A 31-year-old man purchased what was sold as mandrake at a health food store; he developed severe nausea and vomiting but recovered without systemic effects. Chromatographic analysis identified *Podophyllum peltatum* (podophyllotoxin), not *Mandragora officinarum*. Documents commercial mislabeling as a safety risk.

**Additional safety context — scopolamine fatality (Strano-Rossi et al. 2021 [Ref 15]):** An inmate died after smoking scopolamine tablets (buscopan) recreationally. Peripheral blood scopolamine: 14 ng/mL. Pathology: cerebral and pulmonary edema. Demonstrates lethality of scopolamine at toxic concentrations; directly relevant to *M. autumnalis* preparations.

### Herb–drug interactions

**Evidence-based interactions:**
1. **CYP3A inhibitors (grapefruit juice):** Increase scopolamine AUC to 142% of control, prolonging Tmax significantly (Renner 2005 [Ref 14]) — *mechanistic pharmacokinetic basis, moderate severity*
2. **Other anticholinergics (antihistamines, tricyclic antidepressants, antipsychotics, urological agents):** Additive/synergistic anticholinergic burden — well-established pharmacodynamic interaction; risk of severe toxidrome
3. **CNS depressants (alcohol, opioids, benzodiazepines):** Additive CNS depression (Strano-Rossi 2021 [Ref 15] reports co-ingestion in fatal case)
4. **Cholinesterase inhibitors (donepezil, rivastigmine, galantamine):** Direct pharmacodynamic antagonism — reduces efficacy of both drugs; clinically significant in dementia patients
5. **MAO inhibitors:** Potential interaction based on shared CNS pathways — mechanistic basis proposed but no specific clinical case reports found for Mandragora preparations. Flag for human review.

### Tolerance and dependence
No published data on tolerance development specific to *Mandragora* preparations. Tolerance to anticholinergic effects is recognized with repeated pharmaceutical scopolamine/atropine administration. No physical dependence syndrome or withdrawal has been documented for anticholinergic agents. Compulsive use unlikely given characteristically dysphoric experience (Fatur & Kreft 2021 [Ref 30]).

### Vulnerable populations
- **Elderly:** Enhanced anticholinergic sensitivity; case of severe scopolamine toxicity via transdermal patch documented in 66-year-old (Knuf 2019 [Ref 33])
- **Pregnant women:** Scopolamine crosses placenta; Renner 2005 [Ref 14] notes use requires monitoring in pregnancy, though considered non-teratogenic
- **Cardiac patients:** Tachycardia and supraventricular tachycardia documented in poisoning cases (Tsiligianni 2009 [Ref 29])
- **Patients on cholinesterase inhibitors** for dementia: Pharmacodynamic antagonism
- **Pediatric:** Children particularly vulnerable to anticholinergic toxidrome; case reports for other anticholinergics document severe reactions at lower doses

### Contaminant and adulterant risk
*Mandragora* is wild-harvested with no standardized commercial preparations. Key risks:
- **Misidentification as food plants** (borage, spinach, other leafy vegetables) — documented cause of clinical poisoning (Tsiligianni 2009 [Ref 29])
- **Commercial mislabeling:** North American "mandrake" products may contain *Podophyllum peltatum* (podophyllotoxin) instead of *Mandragora officinarum* (Frasca 1997 [Ref 5]) — radically different and serious toxicology
- **Batch variability:** Alkaloid concentrations vary by species, plant part, developmental stage, and growing conditions; no standardization possible from wild material
- **No regulated commercial supply:** No FDA or EMA-approved products; no quality standards for herbal supplements containing Mandragora

---

## Harm Reduction

Published harm reduction guidance specific to *Mandragora* is absent from the peer-reviewed literature. The following is extrapolated from anticholinergic toxicology literature:

- **Identification:** Extreme caution before consuming any foraged plant in the Mediterranean/Balkan region during spring (berry season). *Mandragora* berries should not be eaten under any circumstances.
- **Antidote:** Physostigmine (a reversible acetylcholinesterase inhibitor that crosses the BBB) is the specific antidote for central anticholinergic syndrome. Available in emergency settings. Effective in documented Mandragora poisoning cases (Tsiligianni 2009 [Ref 29]).
- **Emergency:** Any suspected Mandragora ingestion should be treated as a toxicological emergency; gastric lavage appropriate in early presentation.
- **Recreational use:** The traditional hallucinatory use via flying ointment or oral preparation carries an extremely narrow margin between perceptible effect and severe toxicity or death. No safe recreational dose has been established. Recreational use is extremely rare in contemporary settings and is considered extremely dangerous (Fatur 2021 [Ref 30]).
- **Drug panel detection:** Standard immunoassay drug panels do NOT detect hyoscyamine or scopolamine. Specific LC-MS/MS testing is required for forensic or clinical confirmation (Lo Faro 2020 [Ref 3]; Helander 2019 [Ref 16]).

---

## Legal Status

### United States
**Federal:** *Mandragora officinarum* and its extracts are not scheduled under the Controlled Substances Act (CSA). The plant and extracts are legal to possess, cultivate, buy, and distribute without a federal license. If sold as a dietary supplement, sales must conform to federal supplement law (DSHEA).

**Louisiana:** Louisiana Act No. 159 (effective August 8, 2005) explicitly names *Mandragora officinarum* among 40 plants prohibited when intended for human consumption. The law exempts possession, cultivation, and harvesting for "aesthetic, landscaping, or decorative purposes" [Ref 26].

**Other states:** No other state-level bans on *Mandragora* specifically identified in published literature. ⚠️ Low confidence — flag for human review.

### United Kingdom
The Prescription Only Medicines (Human Use) Order 1997 identifies *Mandragora autumnalis* as a substance which, when included in medicinal products, makes those products prescription only. This applies to *M. autumnalis* specifically — it is unclear whether the legislation covers *M. officinarum*, which is now recognized as a taxonomically distinct species. ⚠️ Flag for legal review [Ref 26].

### European Union
The European Medicines Agency (EMA) does not recognize any *Mandragora* species as an approved herbal medicinal product, substance, or preparation under the European Directive on Traditional Herbal Medicinal Products. No EU-wide scheduling of the plant exists [Ref 26].

### International
*Mandragora* spp. are not scheduled under any of the major UN drug control conventions (1961 Single Convention on Narcotic Drugs, 1971 Convention on Psychotropic Substances, 1988 Convention Against Illicit Traffic). The principal alkaloids hyoscyamine and scopolamine are also not scheduled internationally, though both are controlled as prescription-only pharmaceutical agents in most jurisdictions when manufactured as medicines. Atropine and scopolamine appear on the WHO List of Essential Medicines as legitimate pharmaceuticals (Shim 2022 [Ref 1]).

**Israel, Germany, Australia:** No specific regulatory data found for these jurisdictions. ⚠️ Flag for human review.

---

## Clinical Trials

No clinical trials identified on ClinicalTrials.gov for *Mandragora officinarum* or *Mandragora autumnalis* as an investigational product.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Critical flags (safety-relevant)

1. **⚠️ DOSE VALUES — ALL FLAGGED:** No published dose-response data exists for any *Mandragora* preparation in controlled human studies. All dose thresholds (threshold, common, heavy) across all preparation types are unverified against published sources. Any dose range populated in the DB should be cross-referenced against a clinical case report or pharmacokinetic study and labeled as traditional-use data only.

2. **⚠️ ALKALOID CONTENT DISCREPANCY — FLAG FOR HUMAN REVIEW:** Schlesinger et al. 2019 [Ref 20] confirms biochemically that *M. officinarum* contains high hyoscyamine but no scopolamine. Piatti et al. 2025 [Ref 21] found no detectable hyoscyamine OR scopolamine in their *M. officinarum* HPLC samples. The Monadi 2021 comprehensive review [Ref 36] and older literature describe "atropine and scopolamine" for the genus without species differentiation. The resolution is likely that: (1) *M. officinarum* contains primarily hyoscyamine (not scopolamine); (2) some accessions or plant parts may have very low or no detectable alkaloids; (3) much historical attribution of scopolamine to "Mandragora" conflates species. The generation agent must clearly distinguish M. officinarum from M. autumnalis in the alkaloid profile section.

3. **⚠️ "MANDRAGORINE" — UNRESOLVED:** Commonly cited as the distinctive alkaloid of mandrake in popular and some scientific literature. Not found in PubChem under this name. Appears to be either a historical synonym, a misidentification of another alkaloid, or a spurious compound. Flag for editorial review.

4. **⚠️ TRADITIONAL USE AS ONLY EVIDENCE:** Sections on historical oral dose (Dioscorides), flying ointment effects, and many traditional medicinal uses (insomnia, pain, dysuria, hemorrhoids) rely entirely on traditional-use accounts, historical texts, or review articles that themselves cite historical texts. No clinical confirmations. These sections must be clearly framed as traditional-use data.

5. **⚠️ HERB-DRUG INTERACTIONS:** Only the CYP3A/grapefruit juice interaction with scopolamine has direct mechanistic pharmacokinetic evidence (Renner 2005 [Ref 14]). All other interactions (MAO inhibitors, additive anticholinergics, CNS depressants) are inferred from pharmacological principles or from case reports of pharmaceutical scopolamine/atropine — not from Mandragora plant preparations specifically.

6. **⚠️ MISIDENTIFICATION RISK IS THE DOMINANT SAFETY ISSUE:** The greatest real-world harm pathway for *Mandragora* is consumption of berries or leaves mistaken for food plants. This should be prominently featured in any article.

### Data absent from published literature

- No LD50 data for whole-plant *Mandragora* preparations in any species
- No controlled human pharmacokinetic studies for any *Mandragora* preparation
- No clinical trials registered or completed
- No quantified dose-response data for any preparation type
- No published data on dependence, tolerance, or withdrawal specific to Mandragora
- No information found on regulatory status in Germany, Australia, Israel — low confidence
- Quantified alkaloid concentrations by plant part (root vs. leaf vs. fruit vs. seed) are available in older capillary GC studies for *M. autumnalis* (0.2% atropine in roots at flowering stage) but comprehensive HPLC-confirmed data across plant parts for both species is absent
- No published data on contaminant profiles (heavy metals, pesticides, mycotoxins) in wild-harvested Mandragora material

### Source quality note
The richest evidence base for this article comes from: (1) molecular alkaloid chemistry studies (Schlesinger 2019 [Ref 20]); (2) toxicology case reports (Tsiligianni 2009 [Ref 29]; Nikolaou 2012 [Ref 4]); (3) pharmacokinetics of isolated alkaloids (Renner 2005 [Ref 14]); and (4) ethnobotanical/historical literature (Dafni 2019 [Ref 8]; Dafni 2021 [Ref 9]). The comprehensive genus review (Monadi 2021 [Ref 36]) is the strongest secondary synthesis but does not distinguish species-level alkaloid differences with the precision of the primary molecular study.